WO2008145681A3 - Ccr2 receptor antagonists and uses thereof - Google Patents

Ccr2 receptor antagonists and uses thereof Download PDF

Info

Publication number
WO2008145681A3
WO2008145681A3 PCT/EP2008/056573 EP2008056573W WO2008145681A3 WO 2008145681 A3 WO2008145681 A3 WO 2008145681A3 EP 2008056573 W EP2008056573 W EP 2008056573W WO 2008145681 A3 WO2008145681 A3 WO 2008145681A3
Authority
WO
WIPO (PCT)
Prior art keywords
receptor antagonists
ccr2 receptor
ccr2
pulmonarydiseases
copd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/056573
Other languages
French (fr)
Other versions
WO2008145681A2 (en
Inventor
Heiner Ebel
Stefan Peters
Silke Hobbie
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boehringer Ingelheim International GmbH
Original Assignee
Boehringer Ingelheim International GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim International GmbH filed Critical Boehringer Ingelheim International GmbH
Priority to US12/602,274 priority Critical patent/US8653262B2/en
Priority to EP08760165.4A priority patent/EP2155689B1/en
Priority to CA2687931A priority patent/CA2687931C/en
Priority to JP2010509818A priority patent/JP5603770B2/en
Publication of WO2008145681A2 publication Critical patent/WO2008145681A2/en
Publication of WO2008145681A3 publication Critical patent/WO2008145681A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The present invention relates to novel antagonists for CCR2 (CC chemokine receptor 2) and their use for providing medicaments for treating conditions and diseases, especially pulmonarydiseases like asthma and COPD.
PCT/EP2008/056573 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof Ceased WO2008145681A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
US12/602,274 US8653262B2 (en) 2007-05-31 2008-05-29 CCR2 receptor antagonists and uses thereof
EP08760165.4A EP2155689B1 (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof
CA2687931A CA2687931C (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof
JP2010509818A JP5603770B2 (en) 2007-05-31 2008-05-29 CCR2 receptor antagonist and use thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07109376 2007-05-31
EP07109376.9 2007-05-31

Publications (2)

Publication Number Publication Date
WO2008145681A2 WO2008145681A2 (en) 2008-12-04
WO2008145681A3 true WO2008145681A3 (en) 2009-03-05

Family

ID=38752546

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/056573 Ceased WO2008145681A2 (en) 2007-05-31 2008-05-29 Ccr2 receptor antagonists and uses thereof

Country Status (8)

Country Link
US (1) US8653262B2 (en)
EP (1) EP2155689B1 (en)
JP (1) JP5603770B2 (en)
AR (1) AR066799A1 (en)
CA (1) CA2687931C (en)
CL (1) CL2008001593A1 (en)
TW (1) TW200904434A (en)
WO (1) WO2008145681A2 (en)

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2455382B1 (en) 2005-12-13 2016-10-26 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
DE102006039003A1 (en) 2006-08-19 2008-02-21 Boehringer Ingelheim Pharma Gmbh & Co. Kg New connections
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
EP3070090B1 (en) 2007-06-13 2018-12-12 Incyte Holdings Corporation Use of salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h- pyrazol-1-yl)-3- cyclopentylpropanenitrile
CN101821245B (en) 2007-08-14 2012-10-10 贝林格尔·英格海姆国际有限公司 New compounds
EP2025675A1 (en) 2007-08-14 2009-02-18 Boehringer Ingelheim International GmbH Arylsulfonamides with analgetic activity
US20100331298A1 (en) * 2007-12-10 2010-12-30 Cytopathfinder, Inc. Carboxamide Compounds and Their Use
US20110301350A1 (en) * 2008-08-12 2011-12-08 Boehringer Ingelheim International Gmbh Process for preparing cycloalkyl-substituted piperazine compounds
EP2352501B1 (en) * 2008-11-03 2014-01-01 ChemoCentryx, Inc. Compounds for use in the treatment of osteoporosis
HUE025547T2 (en) 2008-12-19 2016-02-29 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
SG176111A1 (en) 2009-05-22 2011-12-29 Incyte Corp 3-[4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl]octane- or heptane-nitrile as jak inhibitors
JP5775070B2 (en) 2009-05-22 2015-09-09 インサイト・コーポレイションＩｎｃｙｔｅ Ｃｏｒｐｏｒａｔｉｏｎ N- (hetero) aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo [2,3-d] pyrimidine and pyrrol-3-yl-pyrrolo [2,3-d] pyrimidine as Janus kinase inhibitors
AR078012A1 (en) 2009-09-01 2011-10-05 Incyte Corp HETEROCICLIC DERIVATIVES OF PIRAZOL-4-IL-PIRROLO (2,3-D) PYRIMIDINS AS INHIBITORS OF THE QUANASA JANUS
ES2674275T3 (en) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
PT3354652T (en) 2010-03-10 2020-07-20 Incyte Holdings Corp Piperidin-4-yl azetidine derivatives as jak1 inhibitors
EP2569298B1 (en) * 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
RS54824B1 (en) 2010-05-21 2016-10-31 Incyte Holdings Corp TOPICAL FORMULATION FOR JAK INHIBITION
EP2576542B1 (en) * 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
AU2011261375B2 (en) 2010-06-04 2016-09-22 Albany Molecular Research, Inc. Glycine transporter-1 inhibitors, methods of making them, and uses thereof
CA2818542A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors
WO2012068440A1 (en) 2010-11-19 2012-05-24 Incyte Corporation Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as jak inhibitors
EP2707367B1 (en) * 2011-05-12 2019-10-09 Bionomics Limited Methods for preparing naphthyridines
MY165963A (en) 2011-06-20 2018-05-18 Incyte Holdings Corp Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as jak inhibitors
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists
TW201313721A (en) 2011-08-18 2013-04-01 Incyte Corp Cyclohexyl azetidine derivatives as JAK inhibitors
UA111854C2 (en) 2011-09-07 2016-06-24 Інсайт Холдінгс Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR JAK INHIBITORS
CA2852160A1 (en) 2011-10-28 2013-05-02 Galderma Research & Development New leukocyte infiltrate markers for rosacea and uses thereof
TW201406761A (en) 2012-05-18 2014-02-16 Incyte Corp Piperidinylcyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as JAK inhibitors
CN113384546A (en) 2012-11-15 2021-09-14 因赛特公司 Sustained release dosage forms of ruxolitinib
WO2014138168A1 (en) 2013-03-06 2014-09-12 Incyte Corporation Processes and intermediates for making a jak inhibitor
WO2014169087A2 (en) * 2013-04-10 2014-10-16 The Trustees Of Columbia University In The City Of New York Treatment of proximal spinal muscular atrophy
GB201309508D0 (en) 2013-05-28 2013-07-10 Redx Pharma Ltd Compounds
GB201311953D0 (en) * 2013-07-03 2013-08-14 Redx Pharma Ltd Compounds
SG10201801069QA (en) 2013-08-07 2018-03-28 Incyte Corp Sustained release dosage forms for a jak1 inhibitor
US9498467B2 (en) 2014-05-30 2016-11-22 Incyte Corporation Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1
EP3256126B1 (en) * 2015-02-09 2024-03-27 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
EP3053577A1 (en) * 2015-02-09 2016-08-10 F. Hoffmann-La Roche AG Compounds for the treatment of cancer
MX383744B (en) 2015-07-02 2025-03-14 Centrexion Therapeutics Corp (4-((3<i>R</i>,4<i>R</i>)-3-METHOXYTETRAHYDRO-PYRAN-4-YLAMINO)PIPERIDIN-1-YL)(5-METHYL-6-(((2<i>R</i>,6S)-6-(P-TOLYL)TETRAHYDRO-2H-PYRAN-2-YL)METHYLAMINO)PYRIMIDIN-4YL)METHANONE CITRATE
CN112480005B (en) * 2017-11-08 2022-08-19 北京嘉林药业股份有限公司 Compounds and their use for treating cancer
AR113922A1 (en) 2017-12-08 2020-07-01 Incyte Corp LOW DOSE COMBINATION THERAPY FOR THE TREATMENT OF MYELOPROLIFERATIVE NEOPLASMS
EA202091830A1 (en) 2018-01-30 2020-12-29 Инсайт Корпорейшн METHODS AND INTERMEDIATE COMPOUNDS FOR OBTAINING JAK INHIBITOR
MD3773593T2 (en) 2018-03-30 2024-10-31 Incyte Corp Treatment of hidradenitis suppurativa using JAK inhibitors
WO2020113094A1 (en) 2018-11-30 2020-06-04 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
US11833155B2 (en) 2020-06-03 2023-12-05 Incyte Corporation Combination therapy for treatment of myeloproliferative neoplasms
EP4329881A4 (en) * 2021-04-30 2025-06-11 Vanqua Bio, Inc. SMALL MOLECULE MODULATORS OF GLUCOCEREBROSIDASE ACTIVITY AND THEIR USES
TW202413352A (en) 2022-06-13 2024-04-01 日商模數探索股份有限公司 Azacycloalkyl carbonyl cyclic amine compound

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
WO1986006719A1 (en) * 1985-05-15 1986-11-20 Chemie Linz Aktiengesellschaft New pyridazine compositions, production process thereof and fungicides and algicides containing them
WO1999021834A1 (en) * 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
WO2005009976A1 (en) * 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
US20050192302A1 (en) * 2003-12-18 2005-09-01 Chu-Biao Xue 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
WO2005084667A1 (en) * 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2006001958A2 (en) * 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
WO2007003604A2 (en) * 2005-07-04 2007-01-11 Novo Nordisk A/S Hists1mine h3 receptor antagonists
WO2007084868A2 (en) * 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response

Family Cites Families (84)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2068961B (en) 1980-02-13 1983-11-30 Sankyo Co Quinazoline derivatives
ES8802151A1 (en) * 1985-07-31 1988-04-01 Janssen Pharmaceutica Nv Novel (4-substituted-piperazinyl)pyridazines.
DE69325662T2 (en) 1992-10-23 2000-02-10 Merck Sharp & Dohme Ltd., Hoddesdon DOPAMINE RECEPTOR SUBTYPE LIGANDS
JP3166376B2 (en) 1993-02-03 2001-05-14 松下電器産業株式会社 Heat utilization equipment
US5629325A (en) 1996-06-06 1997-05-13 Abbott Laboratories 3-pyridyloxymethyl heterocyclic ether compounds useful in controlling chemical synaptic transmission
US6514977B1 (en) * 1997-05-22 2003-02-04 G.D. Searle & Company Substituted pyrazoles as p38 kinase inhibitors
US6979686B1 (en) * 2001-12-07 2005-12-27 Pharmacia Corporation Substituted pyrazoles as p38 kinase inhibitors
JPH1190106A (en) * 1997-09-26 1999-04-06 Daicel Chem Ind Ltd Simulated moving bed type chromatographic separation device
US6143892A (en) * 1998-11-20 2000-11-07 G. D. Searle & Co. Process for making 5-substituted pyrazoles
US6248755B1 (en) 1999-04-06 2001-06-19 Merck & Co., Inc. Pyrrolidine modulators of chemokine receptor activity
EP1046593A1 (en) * 1999-04-12 2000-10-25 Heineken Technical Services B.V. Closure for container
CA2371583C (en) 1999-05-04 2005-09-13 Schering Corporation Piperazine derivatives useful as ccr5 antagonists
DZ3347A1 (en) 2000-05-22 2001-11-29 Aventis Pharma Inc ARYLMETHYLAMINE DERIVATIVES FOR THEIR USE AS TRYPTASE INHIBITORS
AU2002363236A1 (en) 2001-10-30 2003-05-12 Millennium Pharmaceuticals, Inc. Compounds, pharmaceutical compositions and methods of use therefor
US6806279B2 (en) 2001-12-17 2004-10-19 Sunesis Pharmaceuticals, Inc. Small-molecule inhibitors of interleukin-2
HUP0200849A2 (en) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetyl-pyrrolidine-2-carbonitrile derivatives, pharmaceutical compositions containing them and process for producing them
ES2306859T3 (en) * 2002-03-13 2008-11-16 Janssen Pharmaceutica Nv DERIVATIVES OF SULFONIL AS NEW INHIBITORS OF HISTONE DEACETILASE.
US20040014744A1 (en) 2002-04-05 2004-01-22 Fortuna Haviv Substituted pyridines having antiangiogenic activity
US20040082551A1 (en) 2002-06-05 2004-04-29 Benson Alan G. Novel pyrazoles and their use as p38 kinase inhibitors
WO2004024710A1 (en) 2002-09-13 2004-03-25 Glaxo Group Limited Urea compounds active as vanilloid receptor antagonists for the treatment of pain
GB0229618D0 (en) * 2002-12-19 2003-01-22 Cancer Rec Tech Ltd Pyrazole compounds
WO2004074438A2 (en) 2003-02-14 2004-09-02 Smithkline Beecham Corporation Ccr8 antagonists
BRPI0408284B8 (en) 2003-03-12 2021-05-25 Kudos Pharm Ltd phthalazinone derivatives, their use and pharmaceutical composition comprising them
PL1615909T3 (en) 2003-04-23 2009-01-30 Glaxo Group Ltd Piperazine derivatives and their use for the treatment of neurological and psychiatric diseases
FR2854158B1 (en) 2003-04-25 2006-11-17 Sanofi Synthelabo 2-ACYLAMINO-4-PHENYLETHIAZOLE DERIVATIVES, THEIR PREPARATION AND THEIR THERAPEUTIC USE
WO2005014571A1 (en) 2003-07-18 2005-02-17 Glaxo Group Limited Substituted piperidines as histamine h3 receptor ligands
AU2005230902A1 (en) 2004-03-31 2005-10-20 Janssen Pharmaceutica, N.V. Non-imidazole heterocyclic compounds as histamine H3-receptor ligands
WO2005117909A2 (en) 2004-04-23 2005-12-15 Exelixis, Inc. Kinase modulators and methods of use
WO2005118588A1 (en) 2004-06-02 2005-12-15 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US8071624B2 (en) 2004-06-24 2011-12-06 Incyte Corporation N-substituted piperidines and their use as pharmaceuticals
WO2006012135A1 (en) 2004-06-24 2006-02-02 Janssen Pharmaceutica, N. V. Quaternary salt ccr2 antagonists
WO2006004741A2 (en) 2004-06-28 2006-01-12 Incyte Corporation 3-aminocyclopentanecarboxamides as modulators of chemokine receptors
CA2577191A1 (en) 2004-08-26 2006-03-02 Kudos Pharmaceuticals Limited 4-heteroarylmethyl substituted phthalazinone derivatives
GB0420831D0 (en) * 2004-09-17 2004-10-20 Glaxo Group Ltd Novel compounds
EP1807085B1 (en) * 2004-09-20 2013-08-21 Xenon Pharmaceuticals Inc. Heterocyclic derivatives and their use as stearoyl-coa desaturase inhibitors
GB0421525D0 (en) 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2006038734A1 (en) * 2004-10-08 2006-04-13 Astellas Pharma Inc. Pyridazinone derivatives cytokines inhibitors
UY29219A1 (en) 2004-11-22 2006-04-28 Incyte Corp SALTS OF THE N- (2- (((3R) -1- (TRANS-4-HIDROXI-4- (6-METOXIPIRIDIN-3-IL) -CILOHEXIL) PIRROLIDIN-3-IL) AMINO) -2-OXOETIL) -3- (TRIFLUOROMETIL) BENZAMIDA
DE102004061751A1 (en) * 2004-12-22 2006-07-06 Bayer Healthcare Ag Cyanoguanidine-substituted pyrazolines
AU2005317928B2 (en) * 2004-12-24 2010-06-10 Astrazeneca Ab Heterocyclic compounds as CCR2b antagonists
US20080167322A1 (en) * 2005-02-16 2008-07-10 Pinkerton Anthony B Substituted Pyrazoles as Modulators of Chemokine Receptors
ES2528674T3 (en) 2005-02-17 2015-02-11 Astellas Pharma Inc. Piperidine and piperazine carboxylates as FAAH inhibitors
US20070032475A1 (en) 2005-04-15 2007-02-08 Ye Xiaocong M Novel compounds useful for bradykinin B1 receptor antagonism
CA2606288A1 (en) 2005-04-18 2006-10-26 Neurogen Corporation Subtituted heteroaryl cb1 antagonists
WO2006127587A1 (en) 2005-05-20 2006-11-30 Vertex Pharmaceuticals Incorporated Pyrrolopyridines useful as inhibitors of protein kinase
US7851474B2 (en) * 2005-08-02 2010-12-14 Neurogen Corporation Dipiperazinyl ketones and related analogues
GB0517184D0 (en) 2005-08-22 2005-09-28 Glaxo Group Ltd Compounds
AR055203A1 (en) 2005-08-31 2007-08-08 Otsuka Pharma Co Ltd BENZOTIOPHENE DERIVATIVES WITH ANTIPSYTICAL PROPERTIES
EP1928236B1 (en) 2005-09-27 2011-11-23 Irm Llc Diarylamine-containing compounds and compositions, and their use as modulators of c-kit receptors
JO2769B1 (en) * 2005-10-26 2014-03-15 جانسين فارماسوتيكا ان. في Fast Dissociting Dopamine 2 Receptor Antagonists
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053495A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
RU2008123388A (en) 2005-11-14 2009-12-27 Айрм Ллк (Bm) COMPOUNDS AND COMPOSITIONS AS LXR MODULATORS
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
CN101484424B (en) 2006-02-28 2014-05-14 达特神经科学(开曼)有限公司 Therapeutic compounds
EP2024353A2 (en) * 2006-03-16 2009-02-18 Pfizer Products Inc. Pyrazole compounds
WO2007120574A2 (en) 2006-04-11 2007-10-25 Merck & Co., Inc. Diaryl substituted alkanes
US7807671B2 (en) * 2006-04-25 2010-10-05 Bristol-Myers Squibb Company Diketo-piperazine and piperidine derivatives as antiviral agents
US20100168120A1 (en) 2006-04-28 2010-07-01 Neuromedix Inc. Salts of pyridazine compounds
CA2654358A1 (en) 2006-06-22 2007-12-27 Biovitrum Ab (Publ) Pyridine and pyrazine derivatives as mnk kinase inhibitors
DK2120579T3 (en) 2006-12-28 2014-02-03 Abbvie Inc Inhibitors of poly (ADP-ripose) polymerase
CA2676715A1 (en) * 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of ad and related conditions
JP4785881B2 (en) 2007-02-27 2011-10-05 大塚製薬株式会社 Medicine
CA2687931C (en) 2007-05-31 2016-05-24 Boehringer Ingelheim International Gmbh Ccr2 receptor antagonists and uses thereof
CA2697077C (en) 2007-08-22 2012-10-16 Irm Llc 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors
CN101801952A (en) 2007-10-01 2010-08-11 弗·哈夫曼-拉罗切有限公司 N-heterocyclic biaryl carboxamides as ccr receptor antagonists
EP2220045A1 (en) 2007-11-20 2010-08-25 Janssen Pharmaceutica, N.V. Substituted pyridyl amide compounds as modulators of the histamine h3 receptor
EP2062889A1 (en) 2007-11-22 2009-05-27 Boehringer Ingelheim Pharma GmbH & Co. KG Compounds
CA2705405A1 (en) 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh New compounds
EP2297137A1 (en) 2008-06-18 2011-03-23 F. Hoffmann-La Roche AG Novel heteroaryl carboxamide derivatives
JP5693452B2 (en) 2008-08-04 2015-04-01 シーエイチディーアイ ファウンデーション，インコーポレーテッド Specific kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions and methods of their use
GB0815369D0 (en) 2008-08-22 2008-10-01 Summit Corp Plc Compounds for treatment of duchenne muscular dystrophy
AU2009289378A1 (en) 2008-09-02 2010-03-11 Boehringer Ingelheim International Gmbh Novel benzamides, production thereof, and use thereof as medicaments
HUE025547T2 (en) 2008-12-19 2016-02-29 Boehringer Ingelheim Int Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
CA2750635A1 (en) * 2009-02-23 2010-08-26 Merck Canada Inc. Heterocyclic derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase
ES2674275T3 (en) 2009-12-17 2018-06-28 Centrexion Therapeutics Corporation CCR2 receptor antagonists and uses thereof
US20130143905A1 (en) 2009-12-17 2013-06-06 Boehringer Ingelheim International Gmbh Novel antagonists for ccr2 and uses thereof
EP2569298B1 (en) 2010-05-12 2015-11-25 Boehringer Ingelheim International GmbH Novel ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011141477A1 (en) 2010-05-12 2011-11-17 Boehringer Ingelheim International Gmbh New ccr2 receptor antagonists, method for producing the same, and use thereof as medicaments
WO2011144501A1 (en) 2010-05-17 2011-11-24 Boehringer Ingelheim International Gmbh Ccr2 antagonists and uses thereof
EP2576542B1 (en) 2010-05-25 2015-04-22 Boehringer Ingelheim International GmbH Cyclic amide derivatives of pyridazine-3-carboxylic acids and their use in the treatment of pulmonary, pain, immune related and cardiovascular diseases
EP2576538B1 (en) 2010-06-01 2015-10-28 Boehringer Ingelheim International GmbH New CCR2 antagonists
JP5786257B2 (en) 2011-06-16 2015-09-30 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Novel selective CCR2 antagonist
EP2731941B1 (en) 2011-07-15 2019-05-08 Boehringer Ingelheim International GmbH Novel and selective ccr2 antagonists

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032526A (en) * 1975-10-02 1977-06-28 American Cyanamid Company 1,2-dimethyl-3 or 5-piperazinyl-pyrazolium salts
WO1986006719A1 (en) * 1985-05-15 1986-11-20 Chemie Linz Aktiengesellschaft New pyridazine compositions, production process thereof and fungicides and algicides containing them
WO1999021834A1 (en) * 1997-10-27 1999-05-06 Neurosearch A/S Heteroaryl diazacycloalkanes as cholinergic ligands at nicotinic acetylcholine receptors
WO2003066604A2 (en) * 2002-02-05 2003-08-14 Novo Nordisk A/S Novel aryl- and heteroarylpiperazines
WO2005009976A1 (en) * 2003-07-29 2005-02-03 Novo Nordisk A/S Pyridazinyl- piperazines and their use as histamine h3 receptor ligands
US20050192302A1 (en) * 2003-12-18 2005-09-01 Chu-Biao Xue 3-Cycloalkylaminopyrrolidine derivatives as modulators of chemokine receptors
WO2005084667A1 (en) * 2004-03-03 2005-09-15 Chemocentryx, Inc. Bicyclic and bridged nitrogen heterocycles
WO2006001958A2 (en) * 2004-05-21 2006-01-05 Merck & Co., Inc. Amino cyclopentyl heterocyclic and carbocyclic modulators of chemokine receptor activity
WO2006050389A2 (en) * 2004-11-02 2006-05-11 Northwestern University Pyridazine compounds, compositions and methods
WO2007003604A2 (en) * 2005-07-04 2007-01-11 Novo Nordisk A/S Hists1mine h3 receptor antagonists
WO2007084868A2 (en) * 2006-01-17 2007-07-26 Kalypsys, Inc. Treatment of disorders by activation of the unfolded protein response

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DATABASE CAPLUS [online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; 1992, XP002461758, retrieved from STN Database accession no. 1992:571353 *
HU ET AL: "Development of a novel therapeutic suppressor of brain proinflammatory cytokine up-regulation that attenuates synaptic dysfunction and behavioral deficits", BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, OXFORD, GB, 2007 - 17 October 2006 (2006-10-17), XP002459551, ISSN: 0960-894X *
ROWLEY M ET AL: "4-Heterocyclylpiperidines as Selective High-Affinity Ligands at the Human Dopamine D4 Receptor", JOURNAL OF MEDICINAL CHEMISTRY, AMERICAN CHEMICAL SOCIETY. WASHINGTON, US, vol. 40, 1997, pages 2374 - 2385, XP002173936, ISSN: 0022-2623 *
XU PING ET AL: "Synthesis and anticonvulsant activity of 3-(substituted piperazino)-6-(substituted phenyl)pyridazines", BEIJING YIKE DAXUE XUEBAO, vol. 23, no. 6, 1991, pages 477-80 *

Also Published As

Publication number Publication date
CL2008001593A1 (en) 2009-09-11
US8653262B2 (en) 2014-02-18
JP5603770B2 (en) 2014-10-08
EP2155689B1 (en) 2015-07-08
CA2687931A1 (en) 2008-12-04
TW200904434A (en) 2009-02-01
JP2010528089A (en) 2010-08-19
EP2155689A2 (en) 2010-02-24
WO2008145681A2 (en) 2008-12-04
CA2687931C (en) 2016-05-24
US20100204209A1 (en) 2010-08-12
AR066799A1 (en) 2009-09-16

Similar Documents

Publication Publication Date Title
WO2008145681A3 (en) Ccr2 receptor antagonists and uses thereof
MY160471A (en) New ccr2 receptor antagonists and uses thereof
EP1732917B8 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
IL186090A0 (en) Cgrp antagonists, method for the production thereof, and their use as medicaments
IL190423A0 (en) Selected cgrp antagonists , methods for the production thereof and their use as medicaments
WO2009061853A3 (en) Mutant interleukin-2 (il-2) polypeptides
WO2008045564A3 (en) Carboxamide compounds and their use as antagonists of the chemokine ccr2 receptor
WO2008005345A3 (en) Compositions of 5-ht3 antagonists and dopamine d2 antagonists for treatment of dopamine-associated chronic conditions
WO2009022311A3 (en) 1,2-diamido-ethylene derivatives as orexin antagonists
IL180874A0 (en) Substituted, bicyclic 8-pyrrolidinoxanthines, method for the production thereof and their use as medicaments
NZ592723A (en) Cyclic pyrimidin-4-carboxamides as ccr2 receptor antagonists for treatment of inflammation, asthma and copd
WO2007122591A3 (en) Pyrazolo-tetrahydro pyridine derivatives as orexin receptor antagonists
WO2007056470A3 (en) Neuropilin antagonists
IL189497A0 (en) Selected cgrp antagonists, methods for the production thereof and their use as medicaments
WO2010039977A3 (en) Heteroaryl antagonists of prostaglandin d2 receptors
WO2007076260A3 (en) Farnesoid x receptor agonists
WO2008046581A3 (en) Substituted tetrahydropyrrolopyrazine compounds and use thereof in medicaments
WO2007076070A3 (en) Modulators of muscarinic receptors
IL181012A0 (en) Substituted 8-aminoalkoxi-xanthines, method for the production thereof and use thereof as medicaments
WO2007126934A3 (en) Amidoethylthioether orexin receptor antagonists
WO2008008359A3 (en) Benzofuro-and benzothienopyryimidine modulators of the histamine h4 receptor
WO2009071689A3 (en) 5-halogen-substituted oxindole derivatives and use thereof for treating vasopressine-dependent diseases
WO2011062437A3 (en) Gonadotropin releasing hormone receptor antagonists, manufacturing method thereof, and pharmaceutical composition containing same
WO2009071690A3 (en) 5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
WO2006048248A3 (en) Novel anthranilamide pyridinureas as vegf receptor kinase imhibitors

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08760165

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2687931

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2010509818

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008760165

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12602274

Country of ref document: US